Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)

CUSIP: 45719W205

Q1 2025 13F Holders as of 31 Mar 2025

Type / Class
Equity / Common Stock, $0.001 par value
Shares outstanding
128,205,929
Total 13F shares
51,462,756
Share change
+1,403,448
Total reported value
$112,702,942
Price per share
$2.19
Number of holders
47
Value change
+$3,027,389
Number of buys
31
Number of sells
6

Quarterly Holders Quick Answers

What is CUSIP 45719W205?
CUSIP 45719W205 identifies IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) as of Q1 2025

As of 31 Mar 2025, Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) was held by 47 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 51,462,756 shares. The largest 10 holders included Sands Capital Ventures, LLC, Soleus Capital Management, L.P., Fairmount Funds Management LLC, PERCEPTIVE ADVISORS LLC, COMMODORE CAPITAL LP, ADAR1 Capital Management, LLC, VANGUARD GROUP INC, Nantahala Capital Management, LLC, Blackstone Inc., and Stonepine Capital Management, LLC. This page lists 47 institutional shareholders reporting positions in this security for the Q1 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.